

Evaluating TIME in lung cancer

Rogel Cancer Center Basic Science Retreat 6-19-2019

Stefanie Galban

Department of Radiology Michigan Medicine, Center for Molecular Imaging (CMI), Rogel Cancer Center

Insight into the pathobiology of lung cancer by understanding the Tumor immune microenvironment (TIME)



the immune contexture and immune metabolism

Inducible Kras* lung cancer model





Oncogenic Kras* is required for tumor maintenance



Controls: single transgenic mice on doxycycline

Inducible Kras* and mutant p53 lung cancer model



Simultaneous activation of Kras* and p53R172H leads to adenocarcinomas



Kras* is required for tumor maintenance of adenocarcinomas



Oncogenic Kras* is required for tumor maintenance in p53 mutant adenocarcinomas



Number of lesions is similar between 'Kras* ON' an 'Kras* ON, P53 ON' mice



Controls: single transgenic mice on doxycycline

Future directions

 Comparison between 'Kras* ON' and 'Kras*ON P53 ON' groups to determine: lesion size, lesion location, cell of origin, metastases to brain and liver.

 Use multiplex immunohistochemistry (OPAL) to characterize immune and tumor cells allowing visualization and analysis of cellular interactions within the tumor microenvironment (ongoing studies with Dr. Frankel's lab).

• Immune Profiling by CYTOF with Dr. Marina Pasca di Magliano's group





Understanding of the link between pulmonary disease and lung cancer



Adapted from Balla et al, J.Radiation and Cancer Research, 2018, Vol (9), Page 165-176 and Nature reviews.

Development of a Syngeneic Mouse Model for Idiopathic pulmonary associated-Lung Cancer



Groups	Inducer	Doses
Healthy lung	-bleo/-LLC-1 luc	Vehicle controls
Fibrotic lung	+bleo/-LLC-1 luc	0.5 mg/kg bleomycin
Lung cancer	-bleo/+LLC-1 luc	1x10^6 LLC-1 luciferase expressing cells
Fibrous and cancerous lung	+bleo/+LLC-1 luc	0.5 mg/kg bleo/1x10^6 cells

Tumor Progression Correlates With CD11b+ Macrophages in Lungs of IPF-LC mice

Δ. 0.5

0.0

- Bleo/- LLC + Bleo/- LLC - Bleo/ + LLC + Bleo/+ LLC



- Bleo/ + LLC + Bleo/ - LLC - Bleo/ + LLC + Bleo/ + LLC

5

Δ.

4x

+ Bleo/+ LLC

4x

- Bleo/+ LLC



Bleo/+LLC



80

+

Δ.

09 cD11b .

> - Bleo/- LLC + Bleo/- LLC - Bleo/+ LLC + Bleo/+ LLC

Development of an Inducible IPF-associated Lung Cancer Mouse Model





Future Directions

- generate IPF-LC GEM mouse model
- Determine the tumor immune microenvironment and metabolomic landscape of IPF-LC.
- Evaluate immune check point-based therapies.
- Determine transcriptomic profiles of murine IPF-LC and patient IPF associated lung cancer tissue.



TIME Promotes Tumors in IPF-LC

Acknowledgements

Galban lab

Cara Spencer Jennifer Lee Kristena Abdelmalak Maya Getachew Morgan Jones Rachel Surowiec Sarah Ferris

Former lab members

April Apfelbaum Carlos Espinoza Kara Monchamps Philip Reed

Pasca di Magliano lab

Marina Pasca di Magliano Tim Frankel Valerie Irizarry-Negron

<u>Metabolomics studies</u>

Costas Lyssiotis Nneka Mbah

Lung focus group

Nithya Ramnath Tim Frankel Kemp Cease Krishnan Raghavendran

Radiation Oncology

Rocky Owen Martha Matuszak, Caitlin Schonewolf Shruti Jolly <u>C. Galban lab</u> Aleksa Fortuna Sundaresh Ram

Funding

Radiology-Seed funding Michael Mosier Defeat DIPG- and ChadTough-foundations Rogel Cancer Center Research Grant



Center for Molecular Imaging

